⚕ GalenOps field
←

SITE003-0393

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2023-06-19

AEs
6
Serious
1
Dropout signal
–

Adverse events

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-07-17 (study day 10); relationship: N

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-24 (study day 79); relationship: N

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-27 (study day 173); relationship: N

severe serious assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-02-16 (study day 224); relationship: N; serious criteria: hospitalization

severe assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-03-07 (study day 244); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-03-19 (study day 256); relationship: N

Data queries

No data queries.